Background: Schwannomatosis is a recently recognized form of neurofibromatosis
Introduction
Schwannomatosis is the third major form of neurofibromatosis, a group of neurogenetic disorders that share a predisposition to multiple nerve sheath tumors. The condition was initially thought to represent a mild form of neurofibromatosis 2 (NF2) since early series included patients with multiple peripheral schwannomas. [1] Research criteria for schwannomatosis were proposed in 1997 [2] , and by 2003, it was clear that schwannomatosis was clinically and genetically distinct from NF2. [3] In 2005, consensus diagnostic criteria for schwannomatosis were adopted for clinical use [4, 5] and were modified the following year to specifically exclude patients who fulfill the NF2 diagnostic criteria (with bilateral vestibular schwannomas on high-quality MRI, firstdegree relative with NF2, or a known constitutional NF2 mutation. [5] Schwannomatosis is uncommon, with an annual incidence of 0.58 cases per 1,000,000 persons. [6] As more cases are identified, the reported phenotype continues to expand and evolve. For example, recent case reports indicate that meningiomas and malignant peripheral nerve sheath tumors (MPNST) occur in the setting of schwannomatosis [7, 8, 9, 10] . Reports on the clinical findings in large cohorts of patients with long follow up are therefore essential for our understanding of the disease phenotype. In this report, we describe the spectrum of clinical findings in 87 patients meeting criteria for schwannomatosis in a tertiary neurofibromatosis clinic.
Methods
The clinical records of patients seen at The Family Center for Neurofibromatosis at Massachusetts General Hospital (MGH) between 1995 and 2011 were retrospectively reviewed. Patients who fulfilled either research criteria (used prior to 2005) [1] , consensus diagnostic criteria [4] , or modified diagnostic criteria [5] for schwannomatosis (Table 1) were included in the study. Clinical, radiographic, and pathologic data were extracted from clinical records with specific attention to age of onset, location of tumors, ophthalmologic evaluation, family history, and other stigmata of NF1 or NF2. All patients were examined by a neurologist in the Neurofibromatosis clinic at MGH. This retrospective study was approved by the Massachusetts General Hospital institutional review board (IRB).
Results

Diagnostic and Research Criteria
Eighty-seven patients who met either research or diagnostic criteria for schwannomatosis were identified. Sixty patients (69%) met research criteria for definite, presumptive, or probable schwannomatosis; 27 did not meet research criteria based on having only one pathologically proven schwannoma. Eighty patients (92%) met criteria for presumptive or definite schwannomatosis based on consensus diagnostic criteria. Seven patients did not meet consensus diagnostic criteria due to lack of high-quality MRI in a patient younger than 45. Sixty-six patients (76%) met the more restrictive modified diagnostic criteria; 21 patients did not meet modified criteria due to lack of internal auditory canal (IAC) protocol on MRI scan. None of the 87 patients met diagnostic criteria for NF1 or NF2.
Patient Characteristics
Of the 87 patients meeting research or diagnostic criteria, 46 (53%) were female.
The median age of initial symptom was 30 years (range, 8-59 years). The median age at diagnosis was 40 years (range, 16-70 years), with a median delay from initial symptom to diagnosis of 7 years (range, 0-39 years). A family history of schwannomatosis was present in 11 individuals (13%) from 7 different families. Fifty patients (57%) initially presented with pain, including 40 (46%) unassociated with a mass and 10 (11%) associated with a mass. Thirty-six patients (41%) presented with a mass, including 24 (27%) with a painless mass, ten with a painful mass (11%), and 2 (2%) whose tumor was found incidentally during other imaging. Nine patients (10%) experienced other symptoms such as numbness or weakness. In 4 patients (5%), the presenting symptoms were unknown.
Nervous system tumors
Among 77 patients with cranial imaging, 7 non-vestibular cranial schwannomas were identified in 7 patients (8%) and 5 meningiomas were identified in 4 patients (5%). Peripheral schwannomas were present in most patients (89%; 77/87 patients), with the arms and legs being most commonly affected (46% and 45%, respectively) followed by the head/neck (29%, 25/87), chest (16%, 14/87), pelvis (15%, 13 
Other clinical manifestations
Subcutaneous masses (presumed tumors) were identified by clinical examination in 23% of patients (20/87) with most presenting with 1-5 masses. In addition to schwannomas, pathologically proven lipomas were excised from eleven (13%) patients, angiolipomas from three (3%), and cutaneous neurofibroma from two (2%).
Ophthalmologic abnormalities were present in a minority of patients who had formal examinations (18%, 7/39), and included single cases of visual field defect, Addis pupil, red/green color blindness, unilateral juvenile cataract, amblyopia, indistinct hyperpigmentation, and undefined ophthalmologic stigmata of neurofibromatosis.
Twenty patients (23%) had at least 1 café-au-lait macule that was larger than 1.5 cm in size; no patients had more than 4. No skin fold freckling was seen in these patients.
Four patients had a history of learning disability (5%), 5 (6%) had an existing diagnosis of scoliosis, and 14 (16%) reported tinnitus.
Surgical Management
Eighty-six patients underwent 217 surgeries for resection of schwannoma 
Prevalence and Management of Pain
The most common symptom reported by schwannomatosis patients was chronic pain (68%, 59/87 patients) which included both local and multifocal/diffuse pain.
Sixteen patients (18%) were disabled by their pain and either had to take extended medical leave from work or were unable to work. Accordingly, pain was the indication for surgery in most patients (80%, 70/87) and for most surgeries (80%, 145/181) for which an indication for surgery was documented. Local pain was completely relieved in less than half of surgeries (39%, 57/145), and recurred in most patients (75%, 43/57) either at the site of the original tumor or due to a new tumor. Local pain was partially relieved after 20/145 (14%) surgeries, and was unchanged after 41/145 (28%) surgeries. The outcome on local pain relief was unknown for 27/145 (19%) surgeries. 
Comorbid Conditions
Eleven patients (12.6%) were diagnosed with 16 malignancies. At initial pathologic review, three patients were diagnosed with MPNST and 1 patient with spindle cell carcinoma. Upon further review by one author with expertise in NF-related pathology (ASR), the pathologic diagnosis was revised in all 4 cases. Two cases of MPNST were re-classified as cellular schwannomas based on their histological features and their diffuse, marked expression of S100 and p16 proteins on immunohistochemistry ( Fig. 1b-d) In accordance with previous reports, the rate of anatomically limited disease was 30%. [4] However, since patients in this study did not receive whole-body MRI scans, asymptomatic tumors in other body regions might have been missed by regional MRI.
Despite the high prevalence of schwannomas, the median delay in diagnosis was 7 years in our population, indicating the need for earlier recognition of symptoms.
Other clinical features associated with NF2 were also present in our patients.
Intracranial meningiomas were identified in 5% of our cohort as compared to an expected prevalence of about 50% in NF2 patients. [13] These tumors usually occurred as solitary tumors in schwannomatosis patients whereas they are often multiple or confluent in NF2 patients. The presence of a meningioma in a schwannomatosis patient was noted in early patient series [3, 14] and recently, multigenerational families with meningiomas and germline SMARCB1 mutations have been described. [10, 9] Other tumors common in NF2-spinal meningiomas and ependymomas-were not found in this series. Finally, there was no common ophthalmologic pathology in schwannomatosis patients. This finding contrasts with that for NF2 patients in whom cataracts are found in up to 80% of patients. [15] Chronic pain remains the hallmark of schwannomatosis. The majority of our patients (68%) experienced chronic pain, and a significant number were disabled by their pain. Despite aggressive management with surgery (99%) and pain medication (62%), most patients did not become pain-free. Furthermore, 20% of patients (28% of women and 12% of men) experienced frequent headaches, which were often described as "migraines". Whether this reflects a misattribution of non-specific pain from other body parts or a separate mechanism remains unclear. Referral to an experienced pain clinic is warranted for schwannomatosis patients with chronic pain.
Depression and anxiety are also common in schwannomatosis patients, with 39% of women and 17% of men reporting a history of these mood disorders. Survey data indicates that patients with schwannomatosis suffer impaired quality of life and higher rates of depression than the normal population [16] . It is likely that the stress of living with a chronic pain, especially pain that is often undiagnosed for years, leads to increased psychosocial stress on these patients. Active surveillance for and treatment of mood disorders is a central aspect of patient care, and appropriate referrals to mindbody programs and psychiatric treatment is warranted.
There is concern for increased risk of malignancy in patients with schwannomatosis, in particular for MPNST and atypical teratoid/rhabdoid tumors (AT/RT) since these tumors have been reported in patients with familial schwannomatosis. [7, 8] In our cohort, three patients were diagnosed with MPNST at initial pathologic review. All 3 diagnoses were revised upon subsequent review, and during this process, we identified features that may cause pathologic misdiagnosis of schwannomatosis-related schwannomas. In one cellular schwannoma, morphological features of classic schwannoma (such as Antoni A and Antoni B regions and Verocay bodies as seen in Fig 1A) were absent, and dense cellularity and mitoses were present. (Fig. 1B) . This schwannoma contained prominent hyperchromatic, atypical nuclei due to ancient change that was misinterpreted as early malignant transformation in a neurofibroma. A second schwannoma with prominent myxoid background (myxoid schwannoma) was misdiagnosed as a neurofibroma (Fig. 1C) . This error led to a clinical diagnosis of NF1 rather than schwannomatosis in this patient, and to misinterpretation of a subsequent specimen as malignant transformation of a neurofibroma rather than schwannoma. In both cases, diffuse expression of S100 protein on immunohistochemistry was helpful in highlighting the monotonous population of neoplastic Schwann cells composing the tumor (Fig. 1D) . As expression of p16 is often associated with early malignant transformation in neurofibromas, diffuse expression of p16 is also helpful in supporting a benign lesion in difficult cases. A third MPNST was reclassified as melanoma based on the presence of a characteristic BRAF mutation that was also present in a pre-existing skin melanoma from the same patient. 
